Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 18, Issue 8, Pages 1144-1151Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458511434607
Keywords
multiple sclerosis; RCT; vitamin D; EDSS; relapse rate; multiple sclerosis functional composite; grip strength; fatigue severity score
Categories
Funding
- University of Tromso
- Research Council of Norway
- Odd Fellows Research Foundation for Multiple Sclerosis
Ask authors/readers for more resources
Background: High vitamin D levels may reduce the risk of relapses and disease progression in multiple sclerosis. Methods: This 96-week randomised controlled trial was designed to assess the effect of vitamin D-3 supplementation on bone mineral density in persons with multiple sclerosis. Supplementation with 20,000 IU vitamin D-3 weekly raised median serum 25-hydroxy vitamin D (25[OH]D) to 121 nmol/L. The modified intention to treat analysis included 35 persons in the vitamin D-3 group and 33 in the placebo group. Participants were age 21 to 50 years and fully ambulatory (median Expanded Disability Status Scale (EDSS) 2.5). We studied the effect of supplementing vitamin D-3 on the exploratory outcomes annualised relapse rate (ARR), EDSS, multiple sclerosis functional composite (MSFC) components, grip strength, and fatigue. Results: After 96 weeks, there was no significant difference between groups in ARR (absolute difference 0.10, 95% CI -0.07 to 0.27; p = 0.25), EDSS (absolute difference -0.01, 95% CI -0.35 to 0.35; p = 0.97), MSFC components, grip strength, or fatigue. Conclusion: Supplementation with 20,000 IU vitamin D-3 weekly did not result in beneficial effects on the measured multiple sclerosis-related outcomes. This study was not powered to address clinical outcomes, but none of the results were suggestive of an effect in this unselected population of fully ambulatory persons with multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available